Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease

Journal of Clinical Pharmacology

Volumn 54, Issue 9, 2014, Pages 1016-1022

  Wiczling, Paweł ^a   Liem, Robert I ^b   Panepinto, Julie A ^c   Garg, Uttam ^d   Abdel Rahman, Susan M ^d   Kearns, Gregory L ^d   Neville, Kathleen A ^d  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c Children's Hospital of Wisconsin   (United States)

^d CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

hydroxyurea; sickle cell disease; therapeutic drug monitoring

Indexed keywords

HYDROXYUREA; ANTISICKLING AGENT;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG URINE LEVEL; ETHNICITY; FEMALE; HUMAN; LEUKOCYTE; MALE; MATHEMATICAL PHENOMENA; MAXIMUM TOLERATED DOSE; MEAN CORPUSCULAR VOLUME; POPULATION MODEL; POPULATION PHARMACOKINETIC; POPULATION RESEARCH; SICKLE CELL ANEMIA; SINGLE DRUG DOSE; STEADY STATE; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; METABOLISM; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; URINE;

ADMINISTRATION, ORAL; ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYDROXYUREA; MALE; MODELS, BIOLOGICAL;

EID: 84905510021     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.303     Document Type: Article

References (30)

1. Mueller BU,. When should hydroxyurea be used for children with sickle cell disease? Pediatrics. 2008; 122 (6): 1365-1366.
2. Heeney MM, Ware RE,. Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am. 2008; 55 (2): 483-501.
3. Steinberg MH,. Pathophysiologically based drug treatment of sickle cell disease. Trends Pharmacol Sci. 2006; 27 (4): 204-210.
4. Pearson HA, Spencer RP, Cornelius EA,. Functional asplenia in sickle-cell anemia. N Engl J Med. 1969; 281 (17): 923-926.
5. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995; 332 (20): 1317-1322.
6. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001; 97 (11): 3628-3632.
7. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood. 2005; 105 (7): 2685-2690.
8. Hoppe C, Vichinsky E, Quirolo K, van Warmerdam J, Allen K, Styles L,. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. J Pediatr Hematol Oncol. 2000; 22 (4): 330-334.
9. Davies SC, Gilmore A,. The role of hydroxyurea in the management of sickle cell disease. Blood Rev. 2003; 17 (2): 99-109.
10. Charache S,. Hydroxyurea as treatment for sickle cell anemia. Hematol Oncol Clin North Am. 1991; 5 (3): 571-583.
11. Halsey C, Roberts IA,. The role of hydroxyurea in sickle cell disease. Br J Haematol. 2003; 120 (2): 177-186.
12. Gwilt PR, Tracewell WG,. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet. 1998; 34 (5): 347-358.
13. Rodriguez GI, Kuhn JG, Weiss GR, et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood. 1998; 91 (5): 1533-1541.
14. Tracewell WG, Trump DL, Vaughan WP, Smith DC, Gwilt PR,. Population pharmacokinetics of hydroxyurea in cancer patients. Cancer Chemother Pharmacol. 1995; 35 (5): 417-422.
15. Gwilt PR, Manouilov KK, McNabb J, Swindells SS,. Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients. J Clin Pharmacol. 2003; 43 (9): 1003-1007.
16. Yan JH, Ataga K, Kaul S, et al. The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. J Clin Pharmacol. 2005; 45 (4): 434-445.
17. Newman EM, Carroll M, Akman SA, et al. Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. Cancer Chemother Pharmacol. 1997; 39 (3): 254-258.
18. Paule I, Sassi H, Habibi A, et al. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen. Orphanet J Rare Dis. 2011; 6: 30.
19. Scott DK, Neville K, Garg U,. Determination of hydroxyurea in serum or plasma using gas chromatography-mass spectrometry (GC-MS). Methods Mol Biol. 2010; 603: 279-287.
20. Beal S, Sheiner LB, Boeckmann A, Bauer RJ,. NONMEM User's Guides. Ellicott City, MD: Icon Development Solutions; 2001 -2009.
21. Beal SL,. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001; 28 (5): 481-504.
22. Savic RM, Jonker DM, Kerbusch T, Karlsson MO,. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007; 34 (5): 711-726.
23. Shen J, Boeckmann A, Vick A,. Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model). J Pharmacokinet Pharmacodyn. 2012; 39 (3): 251-262.
24. Ribbing J, Jonsson EN,. Power, Selection Bias and Predictive Performance of the Population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn. 2004; 31 (2): 109-134.
25. M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13 (2): 143-151.
26. Parke J, Holford NHG, Charles BG,. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999; 59 (1): 19-29.
27. Savic RM, Karlsson MO,. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009; 11 (3): 558-569.
28. Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011; 118 (18): 4985-4991.
29. Beckloff GL, Lerner HJ, Frost D, Russo-Alesi FM, Gitomer S,. Hydroxyurea (NSC-32065) in biologic fluids: dose-concentration relationship. Cancer Chemother Rep. 1965; 48: 57-58.
30. Belt RJ, Haas CD, Kennedy J, Taylor S,. Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer. 1980; 46 (3): 455-462.